If you’ve been following InMed as we have, you’ll notice that this could have massive implications for investors!
As we reported previously InMed just filed a patent for their topical medication for the treatment of glaucoma. This study shows that their proprietary hydro-gel delivery system resulted in enhanced drug uptake, which means potentially better treatment for glaucoma patients.
The InMed-UBC study is the first ever to report hydrogel-mediated cannabinoid nanoparticle delivery to the eye.
While other companies in the space are attempting to biosynthesize cannabinoids, InMed has already successfully biosynthesized cannabinoids and used them in their own drug formulation process, positioining them as a leader in the potential $5 Billion glaucoma market.
This is the kind of textbook activity that drives value in biotech companies.
READ THE RELEASE BELOW:
Vancouver, BC – October 24th, 2017 - InMed Pharmaceuticals, Inc. (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today results from a study co-sponsored by InMed (Dr. Sazzad Hossain, Chief Scientific Officer) and the University of British Columbia (laboratories of Profs. Ujendra Kumar and Vikramaditya Yadav).
The InMed-UBC study is the first ever to report hydrogel-mediated cannabinoid nanoparticle delivery to the eye, resulting in enhanced drug uptake via the cornea and lens. This study further validates the Company’s capacity to conduct a wide spectrum of drug development activities, including:
- biosynthesis of a cannabinoid using a novel E. coli-based system;
- packaging the cannabinoid as a nanoparticle;
- formulation of a cannabinoid drug candidate into a novel, tissue specific delivery vehicle; and
- confirmation of drug delivery and diffusion into a target tissue.
“Importantly, this study offers further validation of InMed’s capabilities in moving the science of cannabinoid pharmaceuticals forward”, said Eric A. Adams, President & CEO of InMed. “Results like this, combined with our expanding patent portfolio and list of publications, on-going R&D, and renowned scientific team and collaborators demonstrates our depth of know-how and supports our trajectory to becoming an industry leader.”
Further disclosure of study data is embargoed pending publication in a peer-reviewed journal.
About InMed
InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed’s proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com.
Contact: InMed Pharmaceuticals Inc.
Chris Bogart
Corporate Development and Investor Relations
T: 604.669.7207
E: chris@inmedpharma.com
Cautionary Note Regarding Forward-Looking Information
This news release contains "forward-looking information" and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about InMed’s capacity to be a full-scale cannabinoid drug development industry leader and its ability to biosynthetically produce cannabinoids using a proprietary E. coli-based system, package the cannabinoid in a nanoparticle, formulate a cannabinoid drug candidate into a novel, tissue specific delivery vehicle, and achieve drug delivery and diffusion into a target tissue; and the expected fundamental value drivers of the company. With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: positive drug development results; demand for InMed’s products; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: technological challenges associated with developing InMed’s proprietary platform technology, including its bioinformatics database drug/disease targeting tool, its cannabinoid biosynthesis technology, its hydrogel cannabinoid product formulation, and its drug product candidates which may not, individually and in aggregate, return their expected level of value; InMed may not be able to find suitable partners; and economic or market conditions may worsen.
A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed’s continuous disclosure filings with Canadian securities regulatory authorities at www.sedar.com. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF